HER2 positive trang 1 tải miễn phí từ TAILIEUCHUNG

"HER2 positive" trang 1 - tải miễn phí từ Tailieuchung

Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: Study protocol of a randomized controlled trial

Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: Study protocol of a randomized controlled trial

6 45 1

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis

7 14 1

Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: Results of a randomized study - SAKK 22/99

Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: Results of a randomized study - SAKK 22/99

9 35 1

Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples

Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples

9 62 1

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

10 9 1

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results

7 43 1

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients

10 43 1

High score of LDH plus dNLR predicts poor survival in patients with HER2- positive advanced breast cancer treated with trastuzumab emtansine

High score of LDH plus dNLR predicts poor survival in patients with HER2- positive advanced breast cancer treated with trastuzumab emtansine

13 23 3

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment

9 8 1

Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients

Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients

8 36 1

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease

7 39 1

Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study

Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study

11 51 1

Histone demethylase GASC1 - a potential prognostic and predictive marker in invasive breast cancer

Histone demethylase GASC1 - a potential prognostic and predictive marker in invasive breast cancer

15 52 1

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: A retrospective single-center study

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: A retrospective single-center study

7 43 3

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2- negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: A propensity score matching study based on SEER database

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2- negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: A propensity score matching study based on SEER database

11 33 1

Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

9 80 0

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review

8 74 1

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2 - positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2 - positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)

10 38 1

Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2- positive gastric cancer

Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2- positive gastric cancer

10 37 1

Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry

Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry

7 31 1

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.